Chemical formula: C₂₈H₃₆N₄O₂S Molecular mass: 492.676 g/mol PubChem compound: 213046
Lurasidone is a selective blocking agent of dopamine and monoamine effects indicated for the treatment of schizophrenia. Lurasidone binds strongly to dopaminergic D2- and to serotonergic 5-HT2A and 5-HT7 receptors. Lurasidone does not bind to histaminergic or muscarinic receptors.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N05AE05 | N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AE Indole derivatives | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| LATUDA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Lurasidone is an active ingredient of these brands:
United States (US)
Australia (AU)
Austria (AT)
Canada (CA)
Croatia (HR)
Ecuador (EC)Estonia (EE)
Finland (FI)
Hong Kong (HK)
Ireland (IE)
Italy (IT)
Japan (JP)
Lithuania (LT)
Netherlands (NL)
Poland (PL)
Romania (RO)
Singapore (SG)
Spain (ES)
Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
